
A Love Letter to the Caregiver
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally

Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally

Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Heather Munoz discusses how blood center infrastructure and flexible collection models are supporting the continued growth of cell and gene therapy. Heather Munoz, principal, global

Program milestone highlights lifesaving impact of civilian prehospital whole blood in San Antonio and beyond On Thursday, Jan. 29, South Texas Blood & Tissue celebrated
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally

Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally

Before sunrise on MLK Day, more than 50 BioBridge Global staff members gathered in downtown San Antonio to take part in the city’s annual MLK

Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Potency assays are a cornerstone of effective cell therapies, but they can also be a source of delay during development. We spoke with Scott Jones,

Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally

Medicare’s New Math on CAR-T Reimbursement Changes: Who Wins, Who Hurts, and What Could Break For a decade, CAR-T has been the ultimate “no-brainer” innovation
Picture a corridor lined with doors: blood cancers, solid tumors, autoimmune, genetic, and rare diseases, all opening wider at once. The field is no longer